X

Trial Profile

A Phase 1/2 Study of SNDX-275 in Combination With Imatinib for Relapsed/Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia.

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 07 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Entinostat (Primary) ; Imatinib (Primary)
Indications Precursor cell lymphoblastic leukaemia-lymphoma
Focus Adverse reactions

Most Recent Events

01 Feb 2013 Actual end date changed from Jan 2012 to Apr 2012 as reported by ClinicalTrials.gov.
12 Jan 2013 Actual initiation date changed from Mar 2010 to 1 Oct 2010 as reported by ClinicalTrials.gov.
11 Jan 2013 Actual end date changed from Mar 2012 to Jan 2012 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com